APEIRON Biologics

APEIRON is a private European biotechnology company headquartered in Vienna, Austria, focusing on the discovery and development of novel cancer immunotherapies and respiratory therapies. In May 2017, APEIRON obtained EU marketing authorization for APN311 (Dinutuximab beta, Qarziba®) for the treatment of pediatric neuroblastoma patients.